Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis
Conditions
Interventions
BMS-986165
Placebo
+1 more
Locations
100
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
The Nephrology Group
Fresno, California, United States
The Regents of The University of California
Los Angeles, California, United States
University of Colorado School of Medicine
Aurora, Colorado, United States
Local Institution - 0029
Gainesville, Florida, United States
Emory University
Atlanta, Georgia, United States
Start Date
July 15, 2019
Primary Completion Date
October 29, 2020
Completion Date
September 17, 2021
Last Updated
October 17, 2022
NCT05126277
NCT07015983
NCT06947460
NCT07107659
NCT07225387
NCT05934149
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions